Shareholders Can Be Confident That Austar Lifesciences' (HKG:6118) Earnings Are High Quality
Apr 02
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedApr 06, 2026
DataAggregated Company Financials
Companies12
- 7D5.0%
- 3M2.8%
- 1Y40.6%
- YTD5.8%
The Life Sciences industry is up 5.0% in the last week, with WuXi Biologics (Cayman) up 8.1%. During this same period, the Viva Biotech Holdings underperformed, falling 5.7%. In the last 12 months, the industry was up 41%. Earnings are forecast to grow by 42% annually.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 06 Apr 2026 | HK$339.7b | HK$47.9b | HK$1.1b | 33.9x | 318.2x | 7.1x |
| Wed, 04 Mar 2026 | HK$341.0b | HK$43.5b | HK$6.1b | 40.9x | 56.1x | 7.8x |
| Fri, 30 Jan 2026 | HK$376.1b | HK$43.2b | HK$6.0b | 43.7x | 62.3x | 8.7x |
| Sun, 28 Dec 2025 | HK$300.4b | HK$42.3b | HK$6.3b | 44.4x | 47.7x | 7.1x |
| Tue, 25 Nov 2025 | HK$310.0b | HK$42.0b | HK$6.2b | 45.9x | 49.8x | 7.4x |
| Thu, 23 Oct 2025 | HK$333.4b | HK$41.8b | HK$6.2b | 46.8x | 53.8x | 8x |
| Sat, 20 Sep 2025 | HK$342.4b | HK$41.9b | HK$6.2b | 47.7x | 55.1x | 8.2x |
| Mon, 18 Aug 2025 | HK$298.2b | HK$37.1b | HK$2.7b | 64.3x | 109.2x | 8x |
| Wed, 16 Jul 2025 | HK$244.6b | HK$37.2b | HK$2.7b | 50.1x | 89.2x | 6.6x |
| Fri, 13 Jun 2025 | HK$236.9b | HK$36.3b | HK$2.6b | 30.8x | 90.7x | 6.5x |
| Sun, 11 May 2025 | HK$188.8b | HK$35.7b | HK$2.6b | 26x | 73.7x | 5.3x |
| Tue, 08 Apr 2025 | HK$154.7b | HK$35.4b | HK$2.5b | 22.8x | 61.2x | 4.4x |
| Thu, 06 Mar 2025 | HK$191.9b | HK$35.8b | -HK$1,057,426,953.28 | 47x | -181.5x | 5.4x |
| Sat, 01 Feb 2025 | HK$157.0b | HK$36.0b | -HK$1,059,719,410.27 | 52.3x | -148.2x | 4.4x |
| Mon, 30 Dec 2024 | HK$158.3b | HK$35.6b | -HK$1,057,434,619.59 | 58.3x | -149.7x | 4.4x |
| Wed, 27 Nov 2024 | HK$132.5b | HK$36.0b | -HK$1,057,906,858.78 | 46.5x | -125.3x | 3.7x |
| Fri, 25 Oct 2024 | HK$157.6b | HK$35.7b | -HK$659,511,842.74 | 30.3x | -239x | 4.4x |
| Sun, 22 Sep 2024 | HK$153.6b | HK$36.1b | -HK$655,358,792.46 | 26.4x | -234.4x | 4.3x |
| Tue, 20 Aug 2024 | HK$102.3b | HK$35.1b | HK$2.5b | 17.8x | 40.8x | 2.9x |
| Thu, 18 Jul 2024 | HK$96.1b | HK$33.4b | HK$3.1b | 18.9x | 31.2x | 2.9x |
| Sat, 15 Jun 2024 | HK$91.5b | HK$33.5b | HK$3.1b | 24x | 29.7x | 2.7x |
| Mon, 13 May 2024 | HK$114.5b | HK$33.6b | HK$3.1b | 29.5x | 37x | 3.4x |
| Wed, 10 Apr 2024 | HK$116.1b | HK$33.6b | HK$3.1b | 34.2x | 37.4x | 3.5x |
| Fri, 08 Mar 2024 | HK$155.5b | HK$32.3b | HK$3.0b | 59.9x | 52.3x | 4.8x |
| Sun, 04 Feb 2024 | HK$124.4b | HK$32.3b | HK$3.0b | 52.6x | 41.8x | 3.9x |
| Tue, 02 Jan 2024 | HK$212.8b | HK$32.6b | HK$3.0b | 90.2x | 70x | 6.5x |
| Thu, 30 Nov 2023 | HK$278.5b | HK$32.4b | HK$3.0b | 86.9x | 92.6x | 8.6x |
| Sat, 28 Oct 2023 | HK$255.3b | HK$30.1b | HK$2.7b | 45.8x | 95.9x | 8.5x |
| Mon, 25 Sep 2023 | HK$230.6b | HK$30.1b | HK$2.7b | 40.7x | 86.3x | 7.7x |
| Wed, 23 Aug 2023 | HK$219.7b | HK$28.9b | HK$3.0b | 24.1x | 72.6x | 7.6x |
| Fri, 21 Jul 2023 | HK$215.7b | HK$28.5b | HK$2.7b | 22.8x | 78.7x | 7.6x |
| Sun, 18 Jun 2023 | HK$251.8b | HK$28.7b | HK$2.8b | 22.8x | 90.6x | 8.8x |
| Tue, 16 May 2023 | HK$244.8b | HK$29.3b | HK$2.9b | 22x | 84.6x | 8.4x |
| Thu, 13 Apr 2023 | HK$259.6b | HK$29.6b | HK$3.0b | 17.6x | 86.8x | 8.8x |
Price to Earnings Ratio
86.8x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 318x which is higher than its 3-year average PE of 11.1x.
- The 3-year average PS ratio of 6.1x is lower than the industry's current PS ratio of 7.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 29% per year over the last three years.
- Meanwhile revenues for these companies have grown 17% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 0.95% | |
| Healthcare | 6.78% | |
| Life Sciences | 5.01% | |
| Clinical Research and Equipment | 5.01% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$34.98 | 8.1% +HK$10.8b | 40.8% | PE25.9x | |
| 2268 WuXi XDC Cayman | HK$61.15 | 6.8% +HK$4.9b | 105.2% | PE45.6x | |
| 1548 Genscript Biotech | HK$12.36 | 12.4% +HK$3.0b | 26.1% | PS3.6x | |
| 2228 XtalPi Holdings | HK$9.60 | 3.3% +HK$1.3b | 141.8% | PE293.1x | |
| 3696 InSilico Medicine Cayman TopCo | HK$57.25 | 0.09% +HK$28.6m | n/a | PS74.4x |
